When the world’s largest pharmaceutical companies need to outsource drug discovery, development, or manufacturing, they need a partner they can trust with their most valuable intellectual property. Syngene International, founded in Bangalore in 1993, serves fourteen of the world’s twenty largest pharma companies — a client list that is itself a credential no marketing campaign can replicate.
Syngene does not sell drugs. It sells scientific capability. The company provides end-to-end services — from early-stage drug discovery through clinical development to commercial manufacturing — across small molecules, large molecules, biologics, antibody-drug conjugates, oligonucleotides, peptides, and cell and gene therapies. Its scientists work on its clients’ molecules under confidentiality, generating no branded products of its own but enabling hundreds of drug development programmes worldwide.
This model requires a different kind of trust than the typical supplier relationship. Syngene’s clients hand over proprietary chemical structures, unpublished biological data, and early-stage clinical results — the crown jewels of pharmaceutical R&D. The fact that 14 of the top 20 global pharma companies do so speaks to the quality of the science, the robustness of the IP protection, and the reliability of the operations. Client retention, not revenue growth, is the real metric.
In FY 2025, more than 5,600 of Syngene’s 8,235 employees were scientists, most holding Master’s or doctoral degrees. This is a company where the workforce is the product.
For most of its history, Syngene operated exclusively from its campuses in Bangalore. The economics were compelling: world-class Indian scientists at a fraction of US labour costs, working in facilities that met FDA and EMA regulatory standards. By FY 2019, 73% of revenue came from US clients, and 95% from international markets overall.
But the CDMO industry is evolving. Clients increasingly want manufacturing capability closer to their end markets, particularly for biologics where cold-chain logistics and supply-chain resilience matter. In FY 2025, Syngene acquired a biologics manufacturing facility in Baltimore, Maryland — its first US production site. The acquisition shifted the geographic revenue mix: US revenue dropped from 74% to 44% of the total (reflecting the broader client base, not a decline), while Europe grew to 28% and India to 15%.
Revenue has grown from $134 million in FY 2016 to $430 million in FY 2025, a trajectory built on deepening relationships with existing clients rather than aggressive client acquisition. The company added roughly 100 new clients over a decade, reaching 400+ active engagements — but the real growth came from expanding the scope and duration of work with its top accounts.
Sources: Syngene International Annual Reports FY2015–16 through FY2024–25. US FDA facility registration data.